(2R,4R)-3-(S-benzoyl-3-mercaptopropionyl)-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid | 82562-46-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,4R)-3-(S-benzoyl-3-mercaptopropionyl)-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid
• 英文别名: (2R,4R)-3-(S-benzoyl-3-mercaptopropanoyl)-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid；(2R,4R)-3-(3-benzoylsulfanylpropanoyl)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
• CAS: 82562-46-7
• 化学式: C₂₀H₁₉NO₅S₂
• 分子量: 417.507
• InChiKey: IBLDDOBXWLJSEZ-MAUKXSAKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  146
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (2R,4R)-3-(S-benzoyl-3-mercaptopropionyl)-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid 在 ammonium hydroxide 作用下， 反应 1.0h， 以83%的产率得到伦唑普利
  参考文献：
  名称：

  Thiol compounds. V. Absolute configuration and crystal structure of (4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid.

  摘要：

  通过核磁共振（NMR）光谱、比旋转测定和 X 射线晶体学，确定了对血管紧张素 I 转换酶（ACE）具有强效抑制活性的(4R)-2-(2-羟基苯基)-3-(3-巯基丙酰基)-4-噻唑烷羧酸（11a），即 SA 446 的绝对构型为(2R, 4R)。文中讨论了 (2R, 4R) - 和 (2S, 4R) - 异构体的结构-活性关系，并介绍了 (4R)-2 芳基-4-噻唑烷羧酸 (1-3) 的立体选择性酰化。

  DOI：

  10.1248/cpb.30.484
• 作为产物：
  描述：

  四氢呋喃 生成 (2R,4R)-3-(S-benzoyl-3-mercaptopropionyl)-2-(2-hydroxyphenyl)-4-thiazolidinecarboxylic acid
  参考文献：
  名称：

  OYA, MASAYUKI;KATO, EISHIN;IWAO, JUN-ICHI;YASUOKA, NORITAKE, CHEM. AND PHARM. BULL., 1982, 30, N 2, 484-493

  摘要：

  DOI：

文献信息

• Sulfur-containing acylamino acids
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US04425333A1

  公开（公告）日：1984-01-10

  This invention relates to the new thiazolidine and pyrrolidine compounds represented by the following general formula ##STR1## wherein p1 Q.sup.1 and Q.sup.2 are methylene or sulfur atom; Z is alkylene containing 1 to 3 carbon atoms; R.sup.1 is hydrogen, alkyl, aryl or heterocycle; R.sup.2 is hydrogen, alkyl, acyl, aryl, heterocycle or mercapto radical; R.sup.3 is hydrogen or alkyl; R.sup.4 is hydrogen, alkyl, aryl, pyrroridine ring formed with R.sup.3, or thiazolidine ring formed with R.sup.3 ; R.sup.5 is hydroxy or amino, which may be substituted by alkyl or aryl. The compounds of this invention are synthesized by the condensation of sulfur-containing acyl thiazolidine carboxylic acid or sulfur-containing acyl pyrrolidine carboxylic acid with amino acid. The compounds of this invention are useful for antihypertensive agent.

  本发明涉及以下一般式所表示的新噻唑啉和吡咯啉化合物：##STR1##其中p1、Q1和Q2是甲基或硫原子；Z是含1至3个碳原子的烷基；R1是氢、烷基、芳基或杂环；R2是氢、烷基、酰基、芳基、杂环或巯基基团；R3是氢或烷基；R4是氢、烷基、芳基、与R3形成的吡咯啉环或与R3形成的噻唑啉环；R5是羟基或氨基，可以被烷基或芳基取代。本发明的化合物是通过硫含量的酰基噻唑啉羧酸或硫含量的酰基吡咯啉羧酸与氨基酸的缩合反应合成的。本发明的化合物对于降压剂具有有用的应用。
• Five-membered heterocyclic compounds
  申请人：Santen Pharmaceutical Co., Ltd.

  公开号：US04464371A1

  公开（公告）日：1984-08-07

  This invention relates to the compound of the general formula [I], process for preparing the compound and antihypertensive agent containing the compound as a main ingredient. ##STR1## wherein R.sup.1 is hydrogen, hydroxy, lower alkyl or lower alkoxy; R.sup.2 is hydrogen, benzoyl or ##STR2## R.sup.3 is hydroxy, lower alkoxy, --NHOH or ##STR3## R.sup.4 is ##STR4## R.sup.5 is hydrogen or halogen; R.sup.6 and R.sup.7 each is hydrogen or lower alkyl; Z is straight or branched alkylene containing 1 to 3 carbon atoms; when R.sup.3 is hydroxy or lower alkoxy, R.sup.2 is ##STR5## and salts thereof, said lower alkyl and lower alkoxy groups contain 1 to 6 carbon atoms.

  本发明涉及一般式[I]的化合物、制备该化合物的方法以及包含该化合物为主要成分的降压药物。其中，R1是氢、羟基、低碳基或低氧基；R2是氢、苯甲酰或；R3是羟基、低氧基、-NHOH或；R4是；R5是氢或卤素；R6和R7各自是氢或低碳基；Z是直链或支链烷基，含1至3个碳原子；当R3是羟基或低氧基时，R2是；以及其盐。所述的低碳基和低氧基基团含1至6个碳原子。
• SULFUR-CONTAINING ACYLAMINO ACIDS
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP0048763A1

  公开（公告）日：1982-04-07

  Novel thiazolidine and pyrrolidine derivatives represented by the general formula: (wherein Q1 and Q2 each represent a methylene group or a sulfur atom, Z represents an alkylene group containing 1 to 3 carbon atoms, R1 represents a hydrogen atom, an alkyl group, an aromatic group or a heterocyclic group, R2 represents a hydrogen atom, an alkyl group, an acyl group, an aromatic group, a heterocyclic group or a substituted mercapto group, R3 represents a hydrogen atom or an alkyl group, R4 represents a hydrogen atom, an alkyl group, an aromatic group, or R3 and R4 are taken together to form a pyrrolidine ring or a thiazolidine ring, and R5 represents a hydroxy group or an amino group, with the respective groups being optionally substituted by an alkyl group or an aromatic group). These compounds are prepared by condensing a sulfur-containing acylthiazo- lidinecarboxylic acid or sulfur-containing acylpyr- rolidinecarboxylic acid with an amino acid. They are useful as antihypertensive agents.

  通式代表的新型噻唑烷和吡咯烷衍生物： (其中 Q1 和 Q2 分别代表亚甲基或硫原子，Z 代表含有 1 至 3 个碳原子的亚烷基，R1 代表氢原子、烷基、芳香基或杂环基，R2 代表氢原子、烷基、酰基、芳香基、杂环基或取代的巯基、R3 代表氢原子或烷基，R4 代表氢原子、烷基、芳香基，或 R3 和 R4 共同形成吡咯烷环或噻唑烷环，R5 代表羟基或氨基，各基团可选择被烷基或芳香基取代）。这些化合物是由含硫酰基噻唑烷羧酸或含硫酰基吡咯烷羧酸与氨基酸缩合而成。它们可用作降压药。
• HETEROCYCLIC 5-MEMBERED RING COMPOUNDS
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP0067885A1

  公开（公告）日：1982-12-29

  Compounds represented by the following general formula (I): wherein R1 represents a hydrogen atom, a hydroxy group, a lower alkyl group or a lower alkoxy group, R2 represents a hydrogen atom, a benzoyl group or R3 represents a hydroxy group, a lower alkoxy group, -NHOH or R5 represents a hydrogen atom or a halogen atom, R6 and R7, which may be the same or different, each represents a hydrogen atom or a lower alkyl group, and Z represents a C1 to C3 straight or branched alkylene group, provided that when R3 represents a hydroxy group or a lower alkoxy group, R2 represents with said lower alkyl group and lower alkoxy group containing 1 to 6 carbon atoms. Process for their preparation, and hypotensives containing the compounds as major compo-

  由以下通式(I)代表的化合物： 其中 R1 代表氢原子、羟基、低级烷基或低级烷氧基，R2 代表氢原子、苯甲酰基或烷氧基，R3 代表氢原子、羟基、低级烷基或低级烷氧基。 R3 代表羟基、低级烷氧基、-NHOH 或 R5 代表氢原子或卤素原子，R6 和 R7 可以相同或不同，各自代表氢原子或低级烷基，Z 代表 C1 至 C3 直链或支链亚烷基，条件是当 R3 代表羟基或低级烷氧基时，R2 代表 所述低级烷基和低级烷氧基含有 1 至 6 个碳原子。其制备方法，以及以这些化合物为主要成分的低增塑剂
• Chem. Pharm. Bull. 1982, 30, 484-493
  作者：

  DOI：——

  日期：——